High risk of lung cancer in surfactant-related gene variant carriers
European Respiratory Journal · 2024
DOI: 10.1183/13993003.01809-2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Alexandre Brudon und 45 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Oncologie Thoracique, Hôpital Bichat, AP-HP, Institut du Cancer AP-HP Nord, Paris, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Pulmonary Surfactant-Associated Protein C, Pulmonary Surfactant-Associated Protein A. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.
Methods
We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.
Results
We identified 99 SRG adult variant carriers ( SFTPA1 (n=18), SFTPA2 (n=31), SFTPC (n=24), ABCA3 (n=14) and NKX2-1 (n=12)), including 20 (20.2%) with lung cancer ( SFTPA1 (n=7), SFTPA2 (n=8), SFTPC (n=3), NKX2-1 (n=2) and ABCA3 (n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) and SFTPA1 / SFTPA2 variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patients versus TRG patients was 18.1 (95% CI 7.1–44.7).
Conclusions
The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service d'Oncologie Thoracique, Hôpital Bichat, AP-HP, Institut du Cancer AP-HP Nord, Paris, France.
- Université Paris Cité, Inserm CIC-EC 1425, Paris, France.
- A. Brudon and M. Legendre contributed equally to this work.
- UF de Génétique Moléculaire, Hôpital Armand Trousseau, AP-HP, Paris, France.
- Sorbonne Université, Inserm UMR-S 933, Maladies Génétiques d'Expression Pédiatrique, Paris, France.
- Département de Médecine Interne, Hôpital Bichat, AP-HP, Paris, France.
ORCID-Profile: Alexandre Brudon, Marie Legendre, Bruno Crestani, Rémi Diesler, Ralph Epaud, Caroline Kannengiesser, Marie-Pierre Debray, Pascale Fanen, Nadia Nathan, Anne Guillaumot, Stephane Jouneau, Guillaume Beltramo, Yurdagul Uzunhan, Sylvain Marchand-Adam, Vincent Cottin, Raphael Borie
Zitieren
APA
Brudon, A., Legendre, M., Mageau, A., Bermudez, J., Bonniaud, P., Bouvry, D., Cadranel, J., Cazes, A., Crestani, B., Dégot, T., Delestrain, C., Diesler, R., Epaud, R., Philippot, Q., Théou-Anton, N., Kannengiesser, C., Ba, I., Debray, M. P., Fanen, P., …, & OrphaLung network (2024). High risk of lung cancer in surfactant-related gene variant carriers. European Respiratory Journal. https://doi.org/10.1183/13993003.01809-2023
Vancouver
Brudon A, Legendre M, Mageau A, Bermudez J, Bonniaud P, Bouvry D, et al. High risk of lung cancer in surfactant-related gene variant carriers. European Respiratory Journal. 2024. doi:10.1183/13993003.01809-2023
BibTeX
@article{Brudon2024,
author = {Brudon, Alexandre and Legendre, Marie and Mageau, Arthur and Bermudez, Julien and Bonniaud, Philippe and Bouvry, Diane and Cadranel, Jacques and Cazes, Aurélie and Crestani, Bruno and Dégot, Tristan and Delestrain, Céline and Diesler, Rémi and Epaud, Ralph and Philippot, Quentin and Théou-Anton, Nathalie and Kannengiesser, Caroline and Ba, Ibrahima and Debray, Marie-Pierre and Fanen, Pascale and Manali, Efrosine and Papiris, Spyros and Nathan, Nadia and Amselem, Serge and Gondouin, Antoine and Guillaumot, Anne and Andréjak, Claire and Jouneau, Stephane and Beltramo, Guillaume and Uzunhan, Yurdagul and Galodé, François and Westeel, Virginie and Mehdaoui, Anas and Hirschi, Sandrine and Leroy, Sylvie and Marchand-Adam, Sylvain and Nunes, Hilario and Picard, Clément and Prévot, Grégoire and Reynaud-Gaubert, Martine and De Vuyst, Paul and Wemeau, Lidwine and Defossez, Gautier and Zalcman, Gérard and Cottin, Vincent and Borie, Raphael and OrphaLung network, OrphaLung network},
title = {High risk of lung cancer in surfactant-related gene variant carriers},
journal = {European Respiratory Journal},
year = {2024},
doi = {10.1183/13993003.01809-2023}
}
EUVIMED